Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results. Phase Ia study of CBP-1008, a bi-specific ligand drug conjugate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback